The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.